Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.
Identifieur interne : 000278 ( PubMed/Corpus ); précédent : 000277; suivant : 000279Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.
Auteurs : P B Chapman ; C. Robert ; J. Larkin ; J B Haanen ; A. Ribas ; D. Hogg ; O. Hamid ; P A Ascierto ; A. Testori ; P C Lorigan ; R. Dummer ; J A Sosman ; K T Flaherty ; I. Chang ; S. Coleman ; I. Caro ; A. Hauschild ; G A McarthurSource :
- Annals of oncology : official journal of the European Society for Medical Oncology [ 1569-8041 ] ; 2017.
Abstract
The BRIM-3 trial showed improved progression-free survival (PFS) and overall survival (OS) for vemurafenib compared with dacarbazine in treatment-naive patients with BRAFV600 mutation-positive metastatic melanoma. We present final OS data from BRIM-3.
DOI: 10.1093/annonc/mdx339
PubMed: 28961848
Links to Exploration step
pubmed:28961848Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.</title><author><name sortKey="Chapman, P B" sort="Chapman, P B" uniqKey="Chapman P" first="P B" last="Chapman">P B Chapman</name><affiliation><nlm:affiliation>Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Robert, C" sort="Robert, C" uniqKey="Robert C" first="C" last="Robert">C. Robert</name><affiliation><nlm:affiliation>Department of Medicine, Institut Gustave Roussy and Paris Sud University, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Larkin, J" sort="Larkin, J" uniqKey="Larkin J" first="J" last="Larkin">J. Larkin</name><affiliation><nlm:affiliation>Department of Medicine, The Royal Marsden NHS Foundation Trust, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Haanen, J B" sort="Haanen, J B" uniqKey="Haanen J" first="J B" last="Haanen">J B Haanen</name><affiliation><nlm:affiliation>Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Ribas, A" sort="Ribas, A" uniqKey="Ribas A" first="A" last="Ribas">A. Ribas</name><affiliation><nlm:affiliation>Department of Medicine, Hematology and Oncology, Jonsson Comprehensive Cancer Center at the University of California Los Angeles, Los Angeles, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Hogg, D" sort="Hogg, D" uniqKey="Hogg D" first="D" last="Hogg">D. Hogg</name><affiliation><nlm:affiliation>Division of Medical Oncology and Hematology, Princess Margaret Hospital and University Health Network, Toronto, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Hamid, O" sort="Hamid, O" uniqKey="Hamid O" first="O" last="Hamid">O. Hamid</name><affiliation><nlm:affiliation>The Angeles Clinic and Research Institute, Melanoma Therapeutics, Los Angeles, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Ascierto, P A" sort="Ascierto, P A" uniqKey="Ascierto P" first="P A" last="Ascierto">P A Ascierto</name><affiliation><nlm:affiliation>Melanoma, Cancer Immunotherapy and Innovative Therapy Unit, Istituto Nazionale Tumori Fondazione G. Pascale, Naples.</nlm:affiliation></affiliation></author><author><name sortKey="Testori, A" sort="Testori, A" uniqKey="Testori A" first="A" last="Testori">A. Testori</name><affiliation><nlm:affiliation>Melanoma and Sarcoma, Istituto Europeo di Oncologia, Milan, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Lorigan, P C" sort="Lorigan, P C" uniqKey="Lorigan P" first="P C" last="Lorigan">P C Lorigan</name><affiliation><nlm:affiliation>Department of Medical Oncology, University of Manchester, Manchester, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Dummer, R" sort="Dummer, R" uniqKey="Dummer R" first="R" last="Dummer">R. Dummer</name><affiliation><nlm:affiliation>Department of Dermatology, University of Zurich, Zurich, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Sosman, J A" sort="Sosman, J A" uniqKey="Sosman J" first="J A" last="Sosman">J A Sosman</name><affiliation><nlm:affiliation>Department of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago.</nlm:affiliation></affiliation></author><author><name sortKey="Flaherty, K T" sort="Flaherty, K T" uniqKey="Flaherty K" first="K T" last="Flaherty">K T Flaherty</name><affiliation><nlm:affiliation>Department of Medicine, Massachusetts General Hospital, Boston.</nlm:affiliation></affiliation></author><author><name sortKey="Chang, I" sort="Chang, I" uniqKey="Chang I" first="I" last="Chang">I. Chang</name><affiliation><nlm:affiliation>Department of Biostatistics in Product Development, Biometrics.</nlm:affiliation></affiliation></author><author><name sortKey="Coleman, S" sort="Coleman, S" uniqKey="Coleman S" first="S" last="Coleman">S. Coleman</name><affiliation><nlm:affiliation>Clinical Department.</nlm:affiliation></affiliation></author><author><name sortKey="Caro, I" sort="Caro, I" uniqKey="Caro I" first="I" last="Caro">I. Caro</name><affiliation><nlm:affiliation>Product Development, Oncology, Genentech Inc., South San Francisco, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Hauschild, A" sort="Hauschild, A" uniqKey="Hauschild A" first="A" last="Hauschild">A. Hauschild</name><affiliation><nlm:affiliation>Department of Dermatology, University Hospital Schleswig-Holstein, Kiel, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Mcarthur, G A" sort="Mcarthur, G A" uniqKey="Mcarthur G" first="G A" last="Mcarthur">G A Mcarthur</name><affiliation><nlm:affiliation>Department of Oncology, Peter MacCallum Cancer Centre, East Melbourne.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28961848</idno><idno type="pmid">28961848</idno><idno type="doi">10.1093/annonc/mdx339</idno><idno type="wicri:Area/PubMed/Corpus">000278</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000278</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.</title><author><name sortKey="Chapman, P B" sort="Chapman, P B" uniqKey="Chapman P" first="P B" last="Chapman">P B Chapman</name><affiliation><nlm:affiliation>Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Robert, C" sort="Robert, C" uniqKey="Robert C" first="C" last="Robert">C. Robert</name><affiliation><nlm:affiliation>Department of Medicine, Institut Gustave Roussy and Paris Sud University, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Larkin, J" sort="Larkin, J" uniqKey="Larkin J" first="J" last="Larkin">J. Larkin</name><affiliation><nlm:affiliation>Department of Medicine, The Royal Marsden NHS Foundation Trust, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Haanen, J B" sort="Haanen, J B" uniqKey="Haanen J" first="J B" last="Haanen">J B Haanen</name><affiliation><nlm:affiliation>Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Ribas, A" sort="Ribas, A" uniqKey="Ribas A" first="A" last="Ribas">A. Ribas</name><affiliation><nlm:affiliation>Department of Medicine, Hematology and Oncology, Jonsson Comprehensive Cancer Center at the University of California Los Angeles, Los Angeles, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Hogg, D" sort="Hogg, D" uniqKey="Hogg D" first="D" last="Hogg">D. Hogg</name><affiliation><nlm:affiliation>Division of Medical Oncology and Hematology, Princess Margaret Hospital and University Health Network, Toronto, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Hamid, O" sort="Hamid, O" uniqKey="Hamid O" first="O" last="Hamid">O. Hamid</name><affiliation><nlm:affiliation>The Angeles Clinic and Research Institute, Melanoma Therapeutics, Los Angeles, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Ascierto, P A" sort="Ascierto, P A" uniqKey="Ascierto P" first="P A" last="Ascierto">P A Ascierto</name><affiliation><nlm:affiliation>Melanoma, Cancer Immunotherapy and Innovative Therapy Unit, Istituto Nazionale Tumori Fondazione G. Pascale, Naples.</nlm:affiliation></affiliation></author><author><name sortKey="Testori, A" sort="Testori, A" uniqKey="Testori A" first="A" last="Testori">A. Testori</name><affiliation><nlm:affiliation>Melanoma and Sarcoma, Istituto Europeo di Oncologia, Milan, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Lorigan, P C" sort="Lorigan, P C" uniqKey="Lorigan P" first="P C" last="Lorigan">P C Lorigan</name><affiliation><nlm:affiliation>Department of Medical Oncology, University of Manchester, Manchester, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Dummer, R" sort="Dummer, R" uniqKey="Dummer R" first="R" last="Dummer">R. Dummer</name><affiliation><nlm:affiliation>Department of Dermatology, University of Zurich, Zurich, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Sosman, J A" sort="Sosman, J A" uniqKey="Sosman J" first="J A" last="Sosman">J A Sosman</name><affiliation><nlm:affiliation>Department of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago.</nlm:affiliation></affiliation></author><author><name sortKey="Flaherty, K T" sort="Flaherty, K T" uniqKey="Flaherty K" first="K T" last="Flaherty">K T Flaherty</name><affiliation><nlm:affiliation>Department of Medicine, Massachusetts General Hospital, Boston.</nlm:affiliation></affiliation></author><author><name sortKey="Chang, I" sort="Chang, I" uniqKey="Chang I" first="I" last="Chang">I. Chang</name><affiliation><nlm:affiliation>Department of Biostatistics in Product Development, Biometrics.</nlm:affiliation></affiliation></author><author><name sortKey="Coleman, S" sort="Coleman, S" uniqKey="Coleman S" first="S" last="Coleman">S. Coleman</name><affiliation><nlm:affiliation>Clinical Department.</nlm:affiliation></affiliation></author><author><name sortKey="Caro, I" sort="Caro, I" uniqKey="Caro I" first="I" last="Caro">I. Caro</name><affiliation><nlm:affiliation>Product Development, Oncology, Genentech Inc., South San Francisco, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Hauschild, A" sort="Hauschild, A" uniqKey="Hauschild A" first="A" last="Hauschild">A. Hauschild</name><affiliation><nlm:affiliation>Department of Dermatology, University Hospital Schleswig-Holstein, Kiel, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Mcarthur, G A" sort="Mcarthur, G A" uniqKey="Mcarthur G" first="G A" last="Mcarthur">G A Mcarthur</name><affiliation><nlm:affiliation>Department of Oncology, Peter MacCallum Cancer Centre, East Melbourne.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Annals of oncology : official journal of the European Society for Medical Oncology</title><idno type="eISSN">1569-8041</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The BRIM-3 trial showed improved progression-free survival (PFS) and overall survival (OS) for vemurafenib compared with dacarbazine in treatment-naive patients with BRAFV600 mutation-positive metastatic melanoma. We present final OS data from BRIM-3.</div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">28961848</PMID><DateCreated><Year>2017</Year><Month>09</Month><Day>29</Day></DateCreated><DateRevised><Year>2017</Year><Month>09</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1569-8041</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>10</Issue><PubDate><Year>2017</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Annals of oncology : official journal of the European Society for Medical Oncology</Title><ISOAbbreviation>Ann. Oncol.</ISOAbbreviation></Journal><ArticleTitle>Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.</ArticleTitle><Pagination><MedlinePgn>2581-2587</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/annonc/mdx339</ELocationID><Abstract><AbstractText Label="Background" NlmCategory="UNASSIGNED">The BRIM-3 trial showed improved progression-free survival (PFS) and overall survival (OS) for vemurafenib compared with dacarbazine in treatment-naive patients with BRAFV600 mutation-positive metastatic melanoma. We present final OS data from BRIM-3.</AbstractText><AbstractText Label="Patients and methods" NlmCategory="UNASSIGNED">Patients were randomly assigned in a 1 : 1 ratio to receive vemurafenib (960 mg twice daily) or dacarbazine (1000 mg/m2 every 3 weeks). OS and PFS were co-primary end points. OS was assessed in the intention-to-treat population, with and without censoring of data for dacarbazine patients who crossed over to vemurafenib.</AbstractText><AbstractText Label="Results" NlmCategory="UNASSIGNED">Between 4 January 2010 and 16 December 2010, a total of 675 patients were randomized to vemurafenib (n = 337) or dacarbazine (n = 338, of whom 84 crossed over to vemurafenib). At the time of database lock (14 August 2015), median OS, censored at crossover, was significantly longer for vemurafenib than for dacarbazine {13.6 months [95% confidence interval (CI) 12.0-15.4] versus 9.7 months [95% CI 7.9-12.8; hazard ratio (HR) 0.81 [95% CI 0.67-0.98]; P = 0.03}, as was median OS without censoring at crossover [13.6 months (95% CI 12.0-15.4) versus 10.3 months (95% CI 9.1-12.8); HR 0.81 (95% CI 0.68-0.96); P = 0.01]. Kaplan-Meier estimates of OS rates for vemurafenib versus dacarbazine were 56% versus 46%, 30% versus 24%, 21% versus 19% and 17% versus 16% at 1, 2, 3 and 4 years, respectively. Overall, 173 of the 338 patients (51%) in the dacarbazine arm and 175 of the 337 (52%) of those in the vemurafenib arm received subsequent anticancer therapies, most commonly ipilimumab. Safety data were consistent with the primary analysis.</AbstractText><AbstractText Label="Conclusions" NlmCategory="UNASSIGNED">Vemurafenib continues to be associated with improved median OS in the BRIM-3 trial after extended follow-up. OS curves converged after ≈3 years, likely as a result of crossover from dacarbazine to vemurafenib and receipt of subsequent anticancer therapies.</AbstractText><AbstractText Label="ClinicalTrials.gov" NlmCategory="UNASSIGNED">NCT01006980.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chapman</LastName><ForeName>P B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robert</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medicine, Institut Gustave Roussy and Paris Sud University, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larkin</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine, The Royal Marsden NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haanen</LastName><ForeName>J B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ribas</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Hematology and Oncology, Jonsson Comprehensive Cancer Center at the University of California Los Angeles, Los Angeles, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hogg</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology and Hematology, Princess Margaret Hospital and University Health Network, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamid</LastName><ForeName>O</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>The Angeles Clinic and Research Institute, Melanoma Therapeutics, Los Angeles, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ascierto</LastName><ForeName>P A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Melanoma, Cancer Immunotherapy and Innovative Therapy Unit, Istituto Nazionale Tumori Fondazione G. Pascale, Naples.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Testori</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Melanoma and Sarcoma, Istituto Europeo di Oncologia, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lorigan</LastName><ForeName>P C</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dummer</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Dermatology, University of Zurich, Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sosman</LastName><ForeName>J A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flaherty</LastName><ForeName>K T</ForeName><Initials>KT</Initials><AffiliationInfo><Affiliation>Department of Medicine, Massachusetts General Hospital, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Biostatistics in Product Development, Biometrics.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coleman</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Department.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caro</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Product Development, Oncology, Genentech Inc., South San Francisco, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hauschild</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Dermatology, University Hospital Schleswig-Holstein, Kiel, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McArthur</LastName><ForeName>G A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Department of Oncology, Peter MacCallum Cancer Centre, East Melbourne.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology, University of Melbourne, Parkville, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Oncol</MedlineTA><NlmUniqueID>9007735</NlmUniqueID><ISSNLinking>0923-7534</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BRAF mutation</Keyword><Keyword MajorTopicYN="N">dacarbazine</Keyword><Keyword MajorTopicYN="N">melanoma</Keyword><Keyword MajorTopicYN="N">vemurafenib</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28961848</ArticleId><ArticleId IdType="pii">4060460</ArticleId><ArticleId IdType="doi">10.1093/annonc/mdx339</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000278 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000278 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:28961848
|texte= Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:28961848" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |